An observational study in Schizophrenia and Metabolic Syndrome, sponsored by Seoul National Hospital. Status unknown at 2 sites in Korea, Republic of. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-06-12.
Sponsored by Seoul National Hospital · Observational
To measure the long-term changes in weight and plasma lipids after switching antipsychotic treatment to aripiprazole
To measure the long-term changes in weight, plasma lipids and fasting blood glucose after switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and in-patients with schizophrenia.
The measurement of weight and lipid profile and fasting blood glucose will be measured at baseline and every 3 months for 1 year.
1,963 studies on the registry are indexed under Metabolic Syndrome; 329 are open to participants now.
This study's planned enrollment of 100 is below the median of 200 across 458 observational studies indexed under Metabolic Syndrome.
Browse Metabolic Syndrome studies →Seoul National Hospital is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
patients with schizophrenia who want to change an antipsychotics due to metabolic side effects
Exclusion Criteria:
patients with schizophrenia who want to change an antipsychotics due to metabolic side effect
weight lipid profile : HDL, LDL, total-cholesterol, triglyceride fasting blood glucose
Time frame: 1 year
prolactin ECG
Time frame: 1 year
This study is status unknown, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National Hospital